- Conditions
- Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung
- Interventions
- AL8326 40 mg, AL8326 60 mg, AL8326 80 mg--stopped
- Drug
- Lead sponsor
- Advenchen Pharmaceuticals, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Weston, Florida • Chicago, Illinois + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1393–1416
of 9,516
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- cisplatin, tirapazamine
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 42 more
- Conditions
- Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
- Interventions
- Globe Pulsed Field System
- Device
- Lead sponsor
- Kardium Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • San Francisco, California + 8 more
- Conditions
- Pregnancy Complications, Maternal Distress, Adverse Birth Outcomes, Infant Conditions
- Interventions
- Digital Health intervention, Community Health Worker, Digital Health Intervention plus Community Health Worker
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 16 Years to 49 Years · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- Durvalumab, Cisplatin, Gemcitabine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,063 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- Cystic Fibrosis
- Interventions
- Tezacaftor/Ivacaftor, Ivacaftor, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more
- Conditions
- Psychosis
- Interventions
- Patients with psychosis will be treated with known antipsychotic medication
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 17 Years to 35 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
- Interventions
- Bardoxolone methyl capsules
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
- Conditions
- Acute Respiratory Failure
- Interventions
- Video Laryngoscope, Direct Laryngoscope
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Denver, Colorado + 9 more
- Conditions
- Clostridoides Difficile Associated Disease
- Interventions
- C.difficile vaccine, Saline Placebo
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 32,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 142
- States / cities
- Athens, Alabama • Guntersville, Alabama • Huntsville, Alabama + 90 more
- Conditions
- Symptomatic Genetic Dilated Cardiomyopathy (DCM)
- Interventions
- Danicamtiv
- Drug
- Lead sponsor
- Kardigan, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more
- Conditions
- HIV Infections, Lipodystrophy
- Interventions
- Pravastatin sodium, Fenofibrate
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2003
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 33 more
- Conditions
- Heart Transplantation
- Interventions
- Daclizumab, Methylprednisolone, Mycophenolate mofetil, Placebo, cyclosporine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 434 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Los Angeles, California • Tampa, Florida + 19 more
- Conditions
- Progressive Supranuclear Palsy
- Interventions
- Not listed
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 942 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2013
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 6 more
- Conditions
- Venous Thrombosis
- Interventions
- Enoxaparin, warfarin, Placebo for apixaban, Placebo for enoxaparin, Placebo for warfarin, apixaban
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,614 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 68 more
- Conditions
- Psoriasis
- Interventions
- 80 mg Ixekizumab Dosing Regimens 1, 2, and 3, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Anaheim, California • Bakersfield, California + 31 more
- Conditions
- Cutaneous T-Cell Lymphoma
- Interventions
- SGX301 (synthetic hypericin), Placebo
- Drug
- Lead sponsor
- Soligenix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Inclisiran sodium 300 mg, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 100 Years
- Enrollment
- 17,004 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 271
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 214 more
- Conditions
- Genital Herpes Simplex Type 2
- Interventions
- VCL-HB01, VCL-HM01, PBS
- Biological
- Lead sponsor
- Vical
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more
- Conditions
- Cryptococcosis
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma
- Interventions
- Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Therapeutic Estradiol
- Procedure · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 5 more
- Conditions
- HIV, Insomnia
- Interventions
- Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised, Resmed ApneaLink Air device (Resmed, San Diego, CA)., Quantitative Sensory testing (QST), OraQuick Advance Rapid HIV 1/2 Swab test, Cluster of Differentiation 4 (CD4) and Viral load
- Diagnostic Test · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Brain and Central Nervous System Tumors, Neurotoxicity
- Interventions
- temozolomide, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
- Drug · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2026
- U.S. locations
- 168
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 117 more
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Interventions
- pramlintide acetate
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 104 more